Libo Pharma Corp. (TPEX:7888)

Taiwan · Delayed Price · Currency is TWD

28.90

-0.90 (-3.02%)

At close: Sep 2, 2026

Libo Pharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	51.73	42.41	27.69	10.99
Research & Development	327.83	265.92	123.46	41.08
Operating Expenses	379.56	308.32	151.16	48.91
Operating Income	-379.56	-308.32	-151.16	-48.91
Interest Expense	-0.03	-0.04	-0.05	-0.07
Interest & Investment Income	10.9	6.85	2.51	2.06
Currency Exchange Gain (Loss)	5.46	5.12	0.9	0.51
Other Non Operating Income (Expenses)	0.14	0.1	-	-
Pretax Income	-363.1	-296.3	-147.8	-46.41
Net Income	-363.1	-296.3	-147.8	-46.41
Net Income to Common	-363.1	-296.3	-147.8	-46.41
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	74	63	47	27
Shares Outstanding (Diluted)	74	63	47	27
Shares Change	34.43%	33.57%	76.69%	-
EPS (Basic)	-4.88	-4.74	-3.16	-1.75
EPS (Diluted)	-4.88	-4.74	-3.16	-1.75
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-446.8	-349.66	-119.84	-36.01
Free Cash Flow Per Share	-6.00	-5.59	-2.56	-1.36
EBITDA	-357.69	-286.65	-134.73	-45.1
D&A For EBITDA	21.88	21.68	16.43	3.81
EBIT	-379.56	-308.32	-151.16	-48.91